跳至主要内容
临床试验/ACTRN12612000551897
ACTRN12612000551897已完成未知

In lung transplant recipients at risk of cytomegalovirus reactivation how does QuantiFERON-CMV directed cytomegalovirus prophylaxis compare to standard of care cytomegalovirus prophylaxis to reduce the incidence of late onset cytomegalovirus infection.

Dr Glenn Westall, for The Alfred Hospital0 个研究点目标入组 119 人开始时间: 2012年5月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
119

研究概览

简要总结

sing the QFN-CMV blood test to dictate the length of antiviral medication cover was shown to reduce the incidence of CMV infection within the transplanted lung.

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Adult (greater than or equal to 18yrs) lung transplant recipients, who are at risk of CMV reactivation, and who have provided written informed consent.

排除标准

  • (1) CMV seronegative recipient and seronegative donor, (2) known ganciclovir resistance, (3) valganciclovir-related neutropenia, (4) BOS grad 3 or BOS with unstable FEV1, (5) hospitalized requiring intubation or mechanical ventilation, (6) active treatment for acute graft rejection, (7) pregnant, lactating, or breast feeding, (8) known hypersensitivity to valganciclovir, or (9) any other condition in the investigators medical opinion that precludes the patients participation.

研究者

发起方
Dr Glenn Westall, for The Alfred Hospital

相似试验